Navigation Links
Progen Announces PI-88 Phase 2 Lung Cancer Results
Date:9/24/2007

BRISBANE, Sept. 24 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures.

The overall data from this trial suggests that no further investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that have failed platinum based first line therapies is warranted. However, nine patients in the study switched to PI-88 after experiencing toxicity or disease progression with docetaxel monotherapy. The data for this patient group suggests a potential survival benefit that Progen intends to investigate further with, amongst others, the clinicians involved in this study.

"We are disappointed, first and foremost, for the patients with non small cell lung cancer that have disease progression following platinum based chemotherapy as treatment options are limited," said Justus Homburg, Progen's Chief Executive Officer. "The outcome of this study has no impact on our Phase 3 registration strategy for patients with post-resection liver cancer which we announced today has been granted fast-track status designation by the U.S. FDA."

"It is quite common for new drugs to show benefit in one patient group but limited benefit in another. To date, PI-88 has shown evidence of benefit in patients with melanoma, multiple myeloma and post-resection liver cancer. In particular, PI-88 may be more active for tumors that are at an earlier disease stage, such as has been demonstrated in the PI-88 Phase 2 primary liver cancer trial" added Homburg. "In that tria
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... , President and Chief Executive Officer of Neurocrine Biosciences, will ... dbAccess Health Care Conference in Boston.   The ... a.m. Eastern Time / 8:20 a.m. Pacific Time.  The presentation ... website at http://www.neurocrine.com . If you ...
(Date:5/23/2013)... May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... technology company, today scheduled a conference call to discuss ... year 2013, ended April 30, 2013. The call will ... 2013. The Company will report financial results for the ... close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... the prostate cancer treatment continuum was highlighted prominently ... the American Urological Association (AUA), in San Diego.  ... invasive high intensity focused ultrasound (HIFU) technology, the ... localize disease, and for urologists to consider minimally ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6
... and create healthy, pain-free habitsBERKELEY, Calif., May 18 ... The Intelligent Body(R) TMJ Program as ... DIY-series of movement reeducation lessons available on CD. ... inexpensive and effective self-care method to help reduce chronic ...
... Novexel, a speciality pharmaceutical,company focused on the ... the significant global problem of microbial resistance,announces that ... NXL103 are,the subject of four posters at the ... (ECCMID). The ECCMID conference is,taking place in Helsinki ...
Cached Medicine Technology:Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ) 2Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ) 3Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki 2Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki 3
(Date:5/24/2013)... About one in five parents think they have little ... or illicit drug use, a new U.S. government survey ... Substance Abuse and Mental Health Services Administration (SAMHSA), since ... the most influential forces helping to shape their child,s ... repeatedly show that parents can make an enormous difference ...
(Date:5/24/2013)... Routinely measuring fractional flow reserve (FFR) using pressure ... chest pain leads to significant changes in the ... results from a study reported at EuroPCR 2013. ... influence management strategy at coronary angiography for diagnosis ... whether routine assessment of FFR in all the ...
(Date:5/24/2013)... about youth and diabetes keeps getting worse. The latest data ... develop Type 2 diabetes are at high risk to develop ... rate than people who acquire Type 2 diabetes as adults. ... seem to be at very high risk for early complications ... pediatric endocrinology in the School of Medicine at The University ...
(Date:5/24/2013)... 24, 2013 The producers of Health ... for Charlotte, North Carolina. It is one of the largest ... companies. The city is populated with more than a million ... residents in both North and South Carolina. Viewers who are ... can tune into WAXN-TV 64 Eyewitness News during the month ...
(Date:5/24/2013)... Residents of San Diego have a new ... expert, and Certified Russian Kettlebell Instructor, Cody Bramlett has ... San Diego, California. The classes take place Monday through ... Initial sign-ups are available online and by clicking ... for years. The bootcamps being offered in San ...
Breaking Medicine News(10 mins):Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2
... and the University of Chicago have announced findings of archeological ... 3500 B.C., leading to the destruction of a city. Clemens ... the excavation was conducted was a war zone. Artifacts from ... in Syria at the Iraqi border. ,The ...
... has become a burden both on the body as well ... a new cardio drug that negates both the above said ... the African-American heart failure patients where it has greatly improved ... of critical care medicine at the University Of Pittsburgh School ...
... area of northeast Delhi resulting in the death of three children ... ,Apparently the family was sitting beside the wall of a ... a press meeting deputy commissioner of police R.L Meena said that ... construction and the cause of the collapse could only be determined ...
... Yoga, Acupuncture, Ayurveda, Chinese movement therapies such as ... just some of the commonly used alternative treatments ... Europe. //Perhaps, this is because it’s strongly perceived ... treatment for cancer with the combination of some ...
... be extensively affected when an influenza pandemic breaks out across ... contraction in the goods and services trade as a result ... for Business. This is the first such conference being held ... inflict on business and health is not easy to predict. ...
... The HIV Women's and Children's Fund has been launched in Singapore ... object of the fund is to help the women and children ... The KK Women's and Children's Hospital (KKH) will administer the Fund, ... as 10% of the new HIV infections in Singapore are accounted ...
Cached Medicine News:Health News:Excavations Reveal Clues Of Early Warfare 2Health News:A cost effective heart failure drug hits the market! 2
... restricted to small central fields, unconventional ... full field capable, all encompassing systems ... ever need to ensure the most ... also include the most important and ...
... Automatic Perimeter, a compact version of ... reputation, provides an accurate visual field ... and has function required for visual,field ... visual field very quickly. It ...
... Endoprosthesis is an innovative device designed to ... patients with abdominal aortic aneurysms (AAA). It ... graft with an outer self-expanding Nitinol support ... material durability. The function of the endoprosthesis ...
... a cast saw to remove a cast from ... in patients. Occasionally patients are cut or burned ... Strip enables healthcare professionals to remove any cast ... provides protection against cuts and burns from the ...
Medicine Products: